Bessemer Group’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.02M Buy
59,061
+18,649
+46% +$2.86M 0.01% 350
2025
Q4
$5.57M Buy
40,412
+24,436
+153% +$3.2M 0.01% 398
2025
Q3
$2.05M Buy
15,976
+403
+3% +$49.2K ﹤0.01% 495
2025
Q2
$1.88M Buy
15,573
+4,284
+38% +$483K ﹤0.01% 483
2025
Q1
$1.26M Buy
11,289
+1,105
+11% +$118K ﹤0.01% 611
2024
Q4
$991K Sell
10,184
-1,190
-10% -$127K ﹤0.01% 766
2024
Q3
$1.31M Sell
11,374
-1,040
-8% -$118K ﹤0.01% 728
2024
Q2
$1.32M Sell
12,414
-159
-1% -$16K ﹤0.01% 607
2024
Q1
$1.22M Sell
12,573
-2,398
-16% -$246K ﹤0.01% 642
2023
Q4
$1.51M Buy
14,971
+263
+2% +$25.4K ﹤0.01% 548
2023
Q3
$1.5M Sell
14,708
-1,675
-10% -$170K ﹤0.01% 531
2023
Q2
$1.65M Buy
16,383
+808
+5% +$80.8K ﹤0.01% 521
2023
Q1
$1.43M Sell
15,575
-1,392
-8% -$122K ﹤0.01% 515
2022
Q4
$1.54M Sell
16,967
-5,029
-23% -$424K ﹤0.01% 497
2022
Q3
$1.67M Buy
21,996
+4,159
+23% +$345K ﹤0.01% 484
2022
Q2
$1.51M Sell
17,837
-261
-1% -$22.9K ﹤0.01% 500
2022
Q1
$1.59M Sell
18,098
-2,153
-11% -$186K ﹤0.01% 396
2021
Q4
$1.77M Sell
20,251
-1,323
-6% -$110K ﹤0.01% 361
2021
Q3
$1.76M Sell
21,574
-491
-2% -$44.2K ﹤0.01% 326
2021
Q2
$2.01M Buy
22,065
+803
+4% +$71.5K ﹤0.01% 316
2021
Q1
$1.82M Buy
21,262
+6,594
+45% +$592K ﹤0.01% 325
2020
Q4
$1.39M Buy
14,668
+334
+2% +$29.2K ﹤0.01% 353
2020
Q3
$1.25M Buy
14,334
+526
+4% +$45.6K ﹤0.01% 375
2020
Q2
$1.21M Sell
13,808
-873
-6% -$75.4K ﹤0.01% 680
2020
Q1
$1.21M Sell
14,681
-203
-1% -$18.1K ﹤0.01% 554
2019
Q4
$1.41M Sell
14,884
-400
-3% -$35.9K ﹤0.01% 665
2019
Q3
$1.33M Buy
15,284
+3,238
+27% +$291K ﹤0.01% 629
2019
Q2
$1.1M Sell
12,046
-893
-7% -$75.6K ﹤0.01% 684
2019
Q1
$1.11M Sell
12,939
-2,197
-15% -$176K ﹤0.01% 606
2018
Q4
$1.16M Buy
15,136
+2,962
+24% +$231K 0.01% 536
2018
Q3
$940K Sell
12,174
-326
-3% -$24.1K ﹤0.01% 593
2018
Q2
$846K Sell
12,500
-780
-6% -$53.8K ﹤0.01% 616
2018
Q1
$963K Sell
13,280
-1,193
-8% -$90.8K ﹤0.01% 592
2017
Q4
$1.09M Sell
14,473
-2,454
-14% -$185K ﹤0.01% 586
2017
Q3
$1.3M Buy
16,927
+2,989
+21% +$226K 0.01% 577
2017
Q2
$1.04M Sell
13,938
-6,351
-31% -$450K ﹤0.01% 652
2017
Q1
$1.35M Buy
20,289
+5,945
+41% +$396K 0.01% 619
2016
Q4
$936K Buy
14,344
+1,398
+11% +$90.7K ﹤0.01% 723
2016
Q3
$916K Sell
12,946
-263
-2% -$19.2K ﹤0.01% 633
2016
Q2
$977K Sell
13,209
-1,834
-12% -$127K 0.01% 468
2016
Q1
$977K Sell
15,043
-11,705
-44% -$796K 0.01% 470
2015
Q4
$2.06M Buy
26,748
+12,666
+90% +$1.01M 0.01% 425
2015
Q3
$1.16M Sell
14,082
-2,010
-12% -$179K 0.01% 556
2015
Q2
$1.42M Buy
16,092
+4,045
+34% +$371K 0.01% 496
2015
Q1
$1.06M Sell
12,047
-4,043
-25% -$359K 0.01% 515
2014
Q4
$1.34M Buy
16,090
+3,803
+31% +$315K 0.01% 436
2014
Q3
$1.04M Sell
12,287
-521
-4% -$42.2K 0.01% 451
2014
Q2
$1.04M Sell
12,808
-841
-6% -$66.1K 0.01% 448
2014
Q1
$1.04M Buy
13,649
+1,013
+8% +$73.8K 0.01% 417
2013
Q4
$910K Buy
12,636
+1,130
+10% +$78.5K 0.01% 446
2013
Q3
$791K Sell
11,506
-933
-8% -$61.7K 0.01% 450
2013
Q2
$788K Buy
+12,439
New +$809K 0.01% 418

Other funds holding NVS

Bessemer Group's NVS Position: Q1 2026 in Review

Bessemer Group increased its Novartis (NVS) stake by 46% in Q1 2026, buying an estimated $2.86M and bringing the position to 59,061 shares worth $9.02M. The position accounts for 0.01% of the portfolio, ranked #350.

Bessemer Group first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Bessemer Group held 59,061 shares of Novartis worth $9.02M as of Q1 2026.
  • Bessemer Group bought 18,649 Novartis shares in Q1 2026, an estimated $2.86M.
  • Novartis made up 0.01% of Bessemer Group's portfolio in Q1 2026, its #350 holding.
  • Bessemer Group first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.